IRLA
IRulya Therapeutics is a clinical-stage biopharmaceutical company developing LAM-001, an inhaled formulation of rapamycin, for pulmonary diseases. Its clinical programs target pulmonary hypertension associated with interstitial lung disease, bronchiolitis obliterans syndrome after lung transplant, and sarcoidosis-associated pulmonary hypertension.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q3 | -2.31 | $0 | -$10M |
| 2026 Q2 | -12.31 | $0 | -$19M |
| 2026 Q1 | 143.40 | $0 | -$8M |
| 2025 Q4 | -150.00 | $0 | -$10M |
| 2025 Q3 | -50.00 | $0 | -$10M |
| 2025 Q2 | -68.00 | $0 | -$12M |
| 2025 Q1 | -68.00 |
| $0 |
| -$10M |
| 2024 Q4 | -56.00 | $0 | -$8M |